Here is the design of a clinical trial:

Official Title: A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)

Included conditions:
- Ovarian Cancer Stage IIIC
- Ovarian Cancer Stage IV

Study Armgroups:
- {'label': 'Neoadjuvant chemotherapy+Durvalumab+Tremelimumab', 'type': 'EXPERIMENTAL', 'description': '1. Neoadjuvant treatment:\n\n   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)\n2. Interval debulking surgery\n3. Adjuvant treatment:\n\nStandard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)', 'interventionNames': ['Drug: Neoadjuvant chemotherapy+Durvalumab+Tremelimumab']}

Interventions:
- {'type': 'DRUG', 'name': 'Neoadjuvant chemotherapy+Durvalumab+Tremelimumab', 'description': '1. Neoadjuvant treatment:\n\n   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)\n2. Interval debulking surgery\n3. Adjuvant treatment:\n\nStandard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)', 'armGroupLabels': ['Neoadjuvant chemotherapy+Durvalumab+Tremelimumab']}

Primary Outcomes:
- {'measure': 'Progression-free survival(PFS)', 'description': '12-months progression-free survival rate will be estimated, and 95% confidence intervals will be calculated.', 'timeFrame': '12 months'}

Please estimate the sample size based on the assumption: 
80% statistical power, 5% of 1-sided type I errors, 10% drop-out rate.
SAMPLE SIZE JUSTIFICATION
      The sample size was calculated based on the 1-sample log-rank test.
      Median PFS is 12 months in advanced-stage ovarian cancer from European Organisation for Research and Treatment of Cancer 55971 and Chemotherapy or Upfront Surgery. The rate of patients with disease-free status at 12 months is expected to be 50% with conventional chemotherapy (SOC). The rate of patients with disease-free status at 12 months is expected to be 70% with the addition of immunotherapy (combination of durvalumab+tremelimumab+SOC followed by durvalumab+SOC) (hazard ratio=0.515). With 80% statistical power and 5% of 1-sided type I errors, 21 patients are needed when patients are accrued for 12 months and followed for 30 months after the last patients is enrolled. The number of expected events would be 14. In anticipation of a 10% drop-out rate, 24 patients will be enrolled in this study.